X-ray screening reveals two promising SARS-CoV-2 drug candidates
Using a high-brilliance X-ray lightsource and protein crystallography, researchers have identified two drugs that inhibit the main protease of SARS-CoV-2.
List view / Grid view
Using a high-brilliance X-ray lightsource and protein crystallography, researchers have identified two drugs that inhibit the main protease of SARS-CoV-2.
Sahm Nasseri discusses promising pre-clinical results of an RNA-based therapeutic developed to treat retinitis pigmentosa type 11.
NFEPP, a new opioid, inhibited colon pain in mice with colitis but did not cause the side effects associated with use of fentanyl.
With the ongoing COVID-19 pandemic, new treatments continue to be urgently needed. One potential solution is antibody therapeutics, which can be used to neutralise the coronavirus and provide future immunity to patients. Here, Dr Laura Walker from Adagio Therapeutics discusses how antibodies can be used in the fight against Severe…
A drug called topotecan (TPT) was administered to mice up to four days after COVID-19 infection, reducing inflammation and morbidity.
A synthetic cannabinoid has shown promise as a treatment for involuntary tremors by activating astrocytes in mouse models.
Scientists have designed a compound named ASO-1 that could help to reduce immune response overactivation in patients with COVID-19.
Researchers have discovered the the compound triptonide is safe, effective and reversible as a male contraceptive in animal models.
Using high-throughput screening techniques, researchers have identified two families of active substances that block SARS-CoV-2 replication.
In pre-clinical studies, a novel treatment decreased plaque formation, meaning it could be used to prevent Alzheimer's disease.
A novel in silico approach applied to drug screening has revealed three potential candidates that may interact with multiple proteins of SARS‐CoV‐2.
Researchers have developed a new screening technique called biological activity-based modelling to identify drug candidates.
According to a new report, the high-throughput screening market will increase at a CAGR of 11.5 percent from 2020 to 2025.
Between January and October 2020, scientists globally have published more than 87,000 papers about the coronavirus.
Vascor (bepridil) could be used to treat COVID-19, according to a new study which screened drugs to repurpose against SARS-CoV-2.